Loomis, Sayles & Company
SWTX

Loomis, Sayles & Company’s SpringWorks Therapeutics SWTX Stock Holding History

Loomis, Sayles & Company’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-532,164
Closed -$30M – 1046
2022
Q1 		$30M Sell
532,164
-10,152
-2% -$581K 0.04% 229
2021
Q4 		$33.6M Sell
542,316
-14,624
-3% -$968K 0.04% 237
2021
Q3 		$35.3M Sell
556,940
-8,638
-2% -$666K 0.04% 222
2021
Q2 		$46.6M Sell
565,578
-11,454
-2% -$870K 0.06% 165
2021
Q1 		$42.5M Sell
577,032
-2,012
-0.3% -$158K 0.06% 179
2020
Q4 		$42M Sell
579,044
-3,243
-0.6% -$209K 0.06% 154
2020
Q3 		$27.8M Buy
582,287
+153,643
+36% +$6.54M 0.04% 181
2020
Q2 		$18M Buy
+428,644
New +$15.3M 0.03% 234

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Loomis, Sayles & Company's SWTX Position: Q2 2022 in Review

Loomis, Sayles & Company sold out of SpringWorks Therapeutics (SWTX) in Q2 2022, closing a stake of 532,164 shares — an estimated $30M sold.

Loomis, Sayles & Company first reported a position in SWTX in Q2 2020 and held it in 8 quarters. The position peaked at $46.6M in Q2 2021. 143 funds tracked by Wall St. Rank hold SWTX as of Q2 2022.

  • Loomis, Sayles & Company reported no remaining SpringWorks Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Loomis, Sayles & Company sold 532,164 SpringWorks Therapeutics shares in Q2 2022, an estimated $30M.
  • Loomis, Sayles & Company first reported a position in SpringWorks Therapeutics in Q2 2020 and held it in 8 quarters.
  • Loomis, Sayles & Company's SpringWorks Therapeutics position peaked at $46.6M in Q2 2021.
  • 143 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2022.

Based on Loomis, Sayles & Company's 13F filing for Q2 2022, filed 5 Aug 2022.